{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:27:56Z","timestamp":1788449276174,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.ajp.2017.05.004","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T13:00:50Z","timestamp":1493902850000},"page":"106-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management"],"prefix":"10.1016","volume":"29","author":[{"given":"Raj","family":"Velamoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajp.2017.05.004_bib0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4088\/JCP.v59n0509a","article-title":"Is risk of neuroleptic malignant syndrome increased in the postpartum period?","volume":"59","author":"Alexander","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2017.05.004_bib0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM IV-TR","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.ajp.2017.05.004_bib0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM V","author":"American Psychiatric Association","year":"2013"},{"issue":"1","key":"10.1016\/j.ajp.2017.05.004_bib0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7125(16)30278-4","article-title":"Neuroleptic malignant syndrome","volume":"77","author":"Caroff","year":"1993","journal-title":"Med. Clin North Am."},{"issue":"5","key":"10.1016\/j.ajp.2017.05.004_bib0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3928\/0048-5713-20000501-09","article-title":"Atypical antipsychotics and neuroleptic malignant syndrome","volume":"30","author":"Caroff","year":"2000","journal-title":"Psychiatr. Ann."},{"issue":"4","key":"10.1016\/j.ajp.2017.05.004_bib0030","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/14737175.7.4.423","article-title":"Neuroleptic malignant syndrome in elderly patients","volume":"7","author":"Caroff","year":"2007","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.ajp.2017.05.004_bib0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0010-440X(99)90071-8","article-title":"The neuroleptic malignant syndrome: an Indian experience","volume":"40","author":"Chopra","year":"1999","journal-title":"Compr. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2017.05.004_bib0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3928\/0048-5713-20000501-10","article-title":"Treatment of neuroleptic malignant, syndrome","volume":"30","author":"Davis","year":"2000","journal-title":"Psychiatr. Ann."},{"key":"10.1016\/j.ajp.2017.05.004_bib0045","unstructured":"Delay J, Deniker P., 1968. Drug-induced extrapyramidal syndromes, in: Vinken P.J., Bruyn G.W. (Eds.), Handbook of Clinical Neurology, vol. 6: Diseases of the Basal Ganglia, Amsterdam, North-Holland, pp. 248\u2013266."},{"issue":"7","key":"10.1016\/j.ajp.2017.05.004_bib0050","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1017\/S1092852900013407","article-title":"Is Lorazepam a treatment for neuroleptic malignant syndrome?","volume":"5","author":"Francis","year":"2000","journal-title":"CNS Spectr."},{"issue":"9","key":"10.1016\/j.ajp.2017.05.004_bib0055","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.4088\/JCP.10m06438","article-title":"An international consensus study of neuroleptic malignant syndrome diagnostic criteria","volume":"72","author":"Gurrera","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2017.05.004_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/JCP.0000000000000640","article-title":"A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome","volume":"37","author":"Gurrera","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.ajp.2017.05.004_bib0065","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/ajp.156.2.169","article-title":"Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome","volume":"156","author":"Gurrera","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2017.05.004_bib0070","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.SMJ.0000145285.28124.66","article-title":"Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly","volume":"98","author":"Hall","year":"2005","journal-title":"South Med. J."},{"issue":"5","key":"10.1016\/j.ajp.2017.05.004_bib0075","first-page":"39","article-title":"Neuroleptic malignant syndrome in the elderly: diagnostic criteria, incidence, risk factors, pathophysiology, and treatment","volume":"14","author":"Hall","year":"2006","journal-title":"Clin. Geriatr."},{"issue":"2","key":"10.1016\/j.ajp.2017.05.004_bib0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00129785-200303020-00002","article-title":"Genetic predisposition to neuroleptic malignant syndrome: implications for antipsychotic therapy","volume":"3","author":"Kawanishi","year":"2003","journal-title":"Am. J. Pharmacogenomics"},{"issue":"September","key":"10.1016\/j.ajp.2017.05.004_bib0085","first-page":"51","article-title":"Benzodiazepines for treatment of neuroleptic nalignant syndrome","volume":"6","author":"Khaldarov","year":"2000","journal-title":"Hosp. Phys."},{"issue":"4","key":"10.1016\/j.ajp.2017.05.004_bib0090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1365-2044.2004.03658.x","article-title":"Dantrolene \u2013 a review of its pharmacology, therapeutic use and new developments","volume":"59","author":"Krause","year":"2004","journal-title":"Anaesthesia"},{"issue":"11","key":"10.1016\/j.ajp.2017.05.004_bib0095","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.143.11.1374","article-title":"Lethal catatonia","volume":"143","author":"Mann","year":"1986","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2017.05.004_bib0100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3928\/0048-5713-20000501-14","article-title":"Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome","volume":"30","author":"Mann","year":"2000","journal-title":"Psychiatr. Ann."},{"issue":"April Suppl. (9)","key":"10.1016\/j.ajp.2017.05.004_bib0105","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1353-8020(02)00125-6","article-title":"Malignant syndrome in Parkinson\u2019s disease: concept and review of the literature","volume":"1","author":"Mizuno","year":"2003","journal-title":"Parkinsonism Relat. Disord."},{"issue":"2","key":"10.1016\/j.ajp.2017.05.004_bib0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/2229-516X.136800","article-title":"Low serum iron as a possible risk factor for Neuroleptic Malignant Syndrome","volume":"4","author":"Patil","year":"2014","journal-title":"Int. J. Appl. Basic Med. Res."},{"issue":"10","key":"10.1016\/j.ajp.2017.05.004_bib0115","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1176\/ajp.143.10.1227","article-title":"Frequency and presentation of the neuroleptic malignant syndrome in a large psychiatric hospital","volume":"143","author":"Pope","year":"1986","journal-title":"Am. J. Psychiatry"},{"issue":"8760","key":"10.1016\/j.ajp.2017.05.004_bib0120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0140-6736(91)90138-F","article-title":"Serum iron and neuroleptic malignant syndrome","volume":"338","author":"Rosebush","year":"1991","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ajp.2017.05.004_bib0125","first-page":"381","article-title":"Drug treatment of the neuroleptic malignant syndrome","volume":"27","author":"Sakkas","year":"1991","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.ajp.2017.05.004_bib0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1176\/appi.psy.50.1.8","article-title":"Neuroleptic malignant syndrome complicating antipsychotic treatment of delirium or agitation in medical and surgical patients: case reports and a review of the literature","volume":"50","author":"Seitz","year":"2009","journal-title":"Psychomatics"},{"issue":"3","key":"10.1016\/j.ajp.2017.05.004_bib0135","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/jnp.4.3.265","article-title":"Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illnesses: a study of 34 cases","volume":"4","author":"Sewell","year":"1992","journal-title":"J. Neuropsychiatr. Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.ajp.2017.05.004_bib0140","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome","volume":"164","author":"Strawn","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2017.05.004_bib0145","first-page":"413","article-title":"Lethal catatonia, neuroleptic malignant syndrome and myositis ossificans","volume":"67","author":"Topka","year":"1996","journal-title":"Nervenarzt"},{"key":"10.1016\/j.ajp.2017.05.004_bib0150","unstructured":"Un\u00fctzer J., Harbin H., Schoenbaum M., Druss B.G., 2013. The collaborative care model: An approach for integrating physical and mental health care in Medicaid health homes. Health Home Resource Center Brief. (May 2013) 1\u201313."},{"key":"10.1016\/j.ajp.2017.05.004_bib0155","series-title":"Applied Research and Evaluation in Community Mental Health Services: An Update of Key Research Domains","first-page":"160","article-title":"Collaborative mental health care: the evolving narrative in primary care","author":"Velamoor","year":"2011"},{"issue":"3","key":"10.1016\/j.ajp.2017.05.004_bib0160","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00005053-199403000-00007","article-title":"Progression of symptoms in neuroleptic malignant syndrome","volume":"182","author":"Velamoor","year":"1994","journal-title":"J. Nerv. Ment. Dis."},{"issue":"9","key":"10.1016\/j.ajp.2017.05.004_bib0165","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/070674379504000907","article-title":"Management of suspected neuroleptic malignant syndrome","volume":"40","author":"Velamoor","year":"1995","journal-title":"Can J. Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2017.05.004_bib0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00002018-199819010-00006","article-title":"Neuroleptic malignant syndrome. Recognition, prevention and Management","volume":"19","author":"Velamoor","year":"1998","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.ajp.2017.05.004_bib0175","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00004583-199211000-00028","article-title":"Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome","volume":"31","author":"Woodbury","year":"1992","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"issue":"2","key":"10.1016\/j.ajp.2017.05.004_bib0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/nedt.2006.2.2.235","article-title":"Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to Lorazepam","volume":"2","author":"Yacoub","year":"2006","journal-title":"Neuropsychiatr. Dis. Treat."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201817301788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201817301788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:28:46Z","timestamp":1761755326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201817301788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":36,"alternative-id":["S1876201817301788"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2017.05.004","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2017.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}